含新药诱导化疗序贯自体造血干细胞移植、维持治疗策略治疗多发性骨髓瘤300例——单中心回顾性研究

OBJECTIVE: To examine the survival and influential factors of an integrated approach of novel agents, autologous hematopoietic stem cell（auto-HSCT）, and maintenance therapy in patients with multiple myeloma（MM）patients from a single center over the past 15 years. METHODS: In our center, 300 MM patients who received an integrated strategy of new agents, auto-HSCT, and maintenance therapy over 15 years were retrospectively and prospectively analyzed. RESULTS: The complete remission rates（CR）and ≥very good partial remission rates（VGPR）following induction therapy, transplantation, and maintenance therapy were respectively 35.3％ and 55.2％, 72.4％ and 80.0％, 89.2％, and 93.4％. When compared to patients receiving double-drug induction, the ≥VGPR and ORR of patients receiving triple-drug induction were improved. No difference existed in CR, ≥VGPR, and ORR between the PAD（bortezomib + liposome doxorubicin+ dexamethasone）and RAD（lenalidomide + liposome doxorubicin + dexamethasone）regimens, but the benefits speed differed. The negative rate of flow minimal residual disease following induction, transplantation, and maintenance was 18.8％（54 cases）, 41.4％（109 cases）, and 58.7％（142 cases）, respectively. The median time to progress（TTP）was 78.7 months and the median overall survival（OS）was 109 months. The median TTP for RISS-Ⅰ-Ⅲ patients were 111.8 months, 77.4 months, and 30.6 months, and the median OS was 118.8 months, 91.4 months, and 48.5 months, respectively. At various points during treatment, the TTP and OS of patients obtaining CR and MRD negative were longer than those of patients who did not obtain CR and MRD negative. TTP was noticeably shorter in high-risk cytogenetic patients compared to standard-risk patients even when CR was acquired during induction. There was no difference in TTP between patients with high-risk cytogenetics and those with standard-risk cytogenetics if MRD negative was acquired during induction. According to a multivariate analysis, the R-ISS stage was a poor predictor of TTP and OS at various treatment intervals. Therapeutic effectiveness was a newly independent prognostic factor following treatment. CONCLUSION: A median survival of almost 10 years is possible for MM patients who receive an integrated strategy of induction regimens followed by auto-HSCT and maintenance therapy, which significantly improves prognosis. However, this approach did not significantly benefit high-risk cytogenetic MM patients.